Table 5.
Clinical outcomes
| Variable | All | De novo | BMS-ISR | DES-ISR | p value |
|---|---|---|---|---|---|
| Number of patients | 481 | 377 | 19 | 85 | – |
| Patients with clinical follow-up | 463 (96.3%) | 360 (95.5%) | 19 (100.0%) | 84 (98.8%) | 0.234 |
| Time to discharge, days | 2.2 ± 5.9 | 2.0 ± 6.3 | 6.0 ± 7.7 | 2.0 ± 2.1 | 0.016 |
| Follow-up time (months)a | 9.4 ± 2.9 | 9.5 ± 2.9 | 9.2 ± 0.6 | 9.3 ± 3.2 | 0.831 |
| In hospital TLF | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | – |
| In hospital Re-PTCA | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | – |
| In hospital CABG | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | – |
| In hospital MI | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | – |
| In hospital cardiac death | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | – |
| Accumulated TLF | 14 (3.0%) | 4 (1.1%) | 2 (10.5%) | 8 (9.5%) | < 0.001 |
| Accumulated TLR | 9 (1.9%) | 3 (0.8%) | 1 (5.3%) | 5 (6.0%) | 0.005 |
| Accumulated Re-PTCA | 9 (1.9%) | 3 (0.8%) | 1 (5.3%) | 5 (6.0%) | 0.005 |
| Accumulated CABG | 1 (0.2%) | 0 (0.0%) | 0 (0.0%) | 1 (1.2%) | 0.104 |
| Accumulated MI | 2 (0.4%) | 0 (0.0%) | 0 (0.0%) | 2 (2.4%) | 0.011 |
| Accumulated cardiac death | 4 (0.9%) | 1 (0.3%) | 1 (5.3%) | 2 (2.4%) | 0.018 |
| Accumulated TVR | 11 (2.4%) | 4 (1.1%) | 1 (5.3%) | 6 (7.1%) | 0.003 |
| Accumulated non-target vessel revascularization | 10 (2.2%) | 5 (1.4%) | 2 (10.5%) | 3 (3.6%) | 0.017 |
| Accumulated vessel thrombosis | 1 (0.2%) | 1 (0.3%) | 0 (0.0%) | 0 (0.0%) | 0.866 |
BMS bare metal stent, CABG coronary artery bypass graft, DES drug-eluting stent, ISR in-stent restenosis, MI myocardial infarction, PTCA percutaneous transluminal coronary angioplasty, TLF target lesion failure, TVR target vessel revascularization
aSingle-factor ANOVA, otherwise χ2 or Fisher’s exact test whenever applicable